Sanara MedTech Q4 EPS $(0.03) Beats $(0.13) Estimate, Sales $17.69M Beat $16.50M Estimate
Portfolio Pulse from Happy Mohamed
Sanara MedTech (NASDAQ:SMTI) reported Q4 earnings with losses of $(0.03) per share, surpassing the $(0.13) estimate, and sales of $17.69M, exceeding the $16.50M estimate. This represents significant improvements over the previous year.
March 25, 2024 | 8:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Sanara MedTech reported Q4 EPS of $(0.03), beating the $(0.13) estimate, and sales of $17.69M, exceeding the $16.50M forecast. Year-over-year improvements were significant.
Beating both earnings and sales estimates significantly, especially with a 94.12% increase over last year's losses and a 15.50% increase in sales, indicates strong performance and operational efficiency. This is likely to instill investor confidence and could lead to a short-term positive impact on SMTI's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100